
Direct thrombin inhibitors: alternatives to heparin.
Publication
, Journal Article
Mureebe, L
Published in: Vascular
2007
After more than 70 years of effective clinical use, heparin remains the most common anticoagulant in use and one of the most commonly prescribed drugs to hospitalized patients. However, the biologic variability and immunogenicity limit its utility. With increasing volumes of vascular intervention and an aging population, an increase in the need for anticoagulation can be anticipated. This article reviews current viable options and barriers to the use of heparin.
Duke Scholars
Published In
Vascular
DOI
ISSN
1708-5381
Publication Date
2007
Volume
15
Issue
6
Start / End Page
372 / 375
Location
England
Related Subject Headings
- Thrombosis
- Thrombin
- Sulfonamides
- Recombinant Proteins
- Pipecolic Acids
- Humans
- Hirudins
- Heparin
- Cardiovascular System & Hematology
- Arginine
Citation
APA
Chicago
ICMJE
MLA
NLM
Mureebe, L. (2007). Direct thrombin inhibitors: alternatives to heparin. Vascular, 15(6), 372–375. https://doi.org/10.2310/6670.2007.00057
Mureebe, Leila. “Direct thrombin inhibitors: alternatives to heparin.” Vascular 15, no. 6 (2007): 372–75. https://doi.org/10.2310/6670.2007.00057.
Mureebe L. Direct thrombin inhibitors: alternatives to heparin. Vascular. 2007;15(6):372–5.
Mureebe, Leila. “Direct thrombin inhibitors: alternatives to heparin.” Vascular, vol. 15, no. 6, 2007, pp. 372–75. Pubmed, doi:10.2310/6670.2007.00057.
Mureebe L. Direct thrombin inhibitors: alternatives to heparin. Vascular. 2007;15(6):372–375.

Published In
Vascular
DOI
ISSN
1708-5381
Publication Date
2007
Volume
15
Issue
6
Start / End Page
372 / 375
Location
England
Related Subject Headings
- Thrombosis
- Thrombin
- Sulfonamides
- Recombinant Proteins
- Pipecolic Acids
- Humans
- Hirudins
- Heparin
- Cardiovascular System & Hematology
- Arginine